Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633007 | 0.79 | KCNH2 (0.50) | KCNH2ALDH1A1HTT | |
| SCHEMBL3886623 | 0.79 | KCNH2 (0.50) | KCNH2CNR1CNR2ALDH1A1HTT | |
| SCHEMBL4503053 | 0.78 | KCNH2 (0.47) | KCNH2CNR1CNR2SLC2A1 | |
| SCHEMBL5636821 | 0.78 | KCNH2 (0.57) | KCNH2SLC2A1 | |
| SCHEMBL5749909 | 0.76 | KCNH2 (0.57) | KCNH2CNR1CNR2CDK9 | |
| SCHEMBL5749905 | 0.76 | KCNH2 (0.49) | KCNH2CNR1CNR2SLC2A1 | |
| SCHEMBL632652 | 0.76 | KCNH2 (0.39) | KCNH2CNR1CNR2 | |
| SCHEMBL6214270 | 0.76 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL591768 | 0.76 | KDM4E (0.51) | KCNH2ALDH1A1HTT | |
| SCHEMBL5750027 | 0.76 | KCNH2 (0.48) | KCNH2CNR1CNR2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | KCNH2 31/4885CNR1 205/4885CNR2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.